RGLS (Regulus Therapeutics) Institutional Ownership : 82.45% (As of Jun. 24, 2025)

View and export this data going back to 2012. Start your Free Trial

What is Regulus Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Regulus Therapeutics's institutional ownership is 82.45%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Regulus Therapeutics's Insider Ownership is 3.13%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Regulus Therapeutics's Float Percentage Of Total Shares Outstanding is 78.76%.

Regulus Therapeutics Institutional Ownership Historical Data

The historical data trend for Regulus Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regulus Therapeutics Institutional Ownership Chart

Regulus Therapeutics Historical Data

The historical data trend for Regulus Therapeutics can be seen below:

	2023-12-31	2024-01-31	2024-02-29	2024-11-30	2024-12-31	2025-01-31	2025-02-28	2025-03-31	2025-04-30	2025-05-31
Institutional Ownership	90.89	92.55	93.21	54.72	54.72	54.71	54.55	54.30	52.43	52.71

Regulus Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Regulus Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regulus Therapeutics Inc (NAS:RGLS) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

7RG0:Germany 7RG0:Germany

Address

4224 Campus Point Court, Suite 210, San Diego, CA, USA, 92121

Website

https://www.regulusrx.com

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Executives

David Baltimore	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Joseph P Hagan	officer: Chief Operating Officer	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Christopher Ray Aker	officer: Sr. VP & General Counsel	C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Crispina Calsada	officer: Chief Financial Officer	C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Preston Klassen	officer: President & Head of R & D	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Kathryn J Collier	director	C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Denis Drygin	officer: Chief Scientific Officer	10628 SCIENCE CENTER DRIVE, SUITE 225, SAN DIEGO CA 92121
Alice Shih-hou Huang	director	10628 SCIENCE CENTER DRIVE, SUITE 225, SAN DIEGO CA 92121
Growth Equity Opportunities V, Llc	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ali Behbahani	10 percent owner	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Paul Edward Walker	director	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Scott D Sandell	10 percent owner
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025